BEIGENE, LTD. RESTATED AMENDMENT NO. 2 TO SHARE PURCHASE AGREEMENTShare Purchase Agreement • October 29th, 2020 • Amgen Inc • Biological products, (no disgnostic substances) • New York
THIS RESTATED AMENDMENT NO. 2 (this “Amendment”) to the SHARE PURCHASE AGREEMENT, dated as of October 31, 2019, as amended on December 6, 2019 (the “Agreement”), is made and entered into as of September 24, 2020, by and among BeiGene, Ltd., an exempted company incorporated in the Cayman Islands (the “Company”), and Amgen Inc., a Delaware corporation (the “Investor”), and restates in its entirety the Amendment No. 2 to the Agreement dated March 17, 2020. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.
AMENDMENT No.2 to the Collaboration AgreementAmgen Inc • October 29th, 2020 • Biological products, (no disgnostic substances)
This Amendment No. 2 (this “Amendment”) is entered into as of August 19, 2020, by and between Amgen Inc. (“Amgen”) and Novartis Pharma AG (“Novartis”). Each of the parties is referred to herein as a “Party” and collectively as the “Parties”.
